OMEICOS Therapeutics

Unlocking the therapeutic power of omega 3 fatty acid metabolites with 1st-in-class therapeutics, targeting both #Inflammation and #MitochondrialDisease #pmd

[OMEICOS Therapeutics @omeicos]

#Sirtuins are key regulators of mitochondrial function and are promising targets for therapeutic interventions and longevity-related strategies. A big "Thank You" to our collaboration partners at the University of Alberta

[OMEICOS Therapeutics @omeicos]

🆕 In-depth mechanistic insights into the cardioprotective properties of our clinical program OMT-28 out in JBC!
https://t.co/65c5x7Y3p8

OMT-28 increases #SIRT1 activity.

[Science & Alliance - UMDF @UMDFScience]

Join us on Monday, Dec 11 at 12:00pm ET for a Bench-to-Bedside Clinical Trials Update with Abliva, @bcmhouston, @GenSightBio, @KhondrionBV, @MinoviaTx, @omeicos, @SaolRx, @StealthBT, Tisento Therapeutics, and @UCBUSA. Register and find more info: https://t.co/JfSaqmI8m4

[OMEICOS Therapeutics @omeicos]

We are making great progress with our PMD-OPTION study in Primary #MitochondrialDisease. The 1st patient entered the interventional study part and receives OMT-28 in 1-daily doses. Meet us at #BioEurope in Munich, learn more about our study design & development strategy in PMD

[OMEICOS Therapeutics @omeicos]

As #WorldMitoWeek begins, we are thrilled to provide a positive update on our PMD-OPTION Phase 2a clinical study evaluating OMT-28 in primary #MitochondrialDisease with first patients being recruited in #Italy and #Germany. For more, please visit: https://t.co/W7dbJeGN5c

[OMEICOS Therapeutics @omeicos]

Interesting article by @_Ktktktktk & deserved recognition for pioneering work in #mitoresearch just ahead of #WorldMitoWeek. We can very much relate to the "beyond ATP" angle of the piece & will update the #MitochondrialDisease community shortly about our activities in the space.

[BioCentury @BioCentury]

Northwestern’s Navdeep Chandel and Harvard’s Vamsi Mootha share the @FNIH_Org 2023 Lurie Prize for their respective pioneering of mitochondrial biology beyond ATP https://t.co/MPGsGwPhpk

[OMEICOS Therapeutics @omeicos]

Excited to announce a EUR 2.5M #grant by @BMBF_Bund complementing our own investment in the upcoming Phase 2a for OMT-28 in Primary Mitochondrial Disease (PMD). Major achievement for the team and further validation for our approach in #MitochondrialHealth. Stay tuned!

[OMEICOS Therapeutics @omeicos]

Based on the established safety profile, biomarker data including #GDF15 #IL6 #PTX3 and #hsCRP, and funding secured from our current investors, we are pleased to expand our OMT-28 development program into Primary Mitochondrial Diseases, with a Phase II start expected for 2023.

[OMEICOS Therapeutics @omeicos]

@MitoNice2022 An invaluable opportunity to meet with the experts in the field of #mitodiseases at this conference in Nice/France - being an excellent place to connect to the #mitocommunity and to discuss OMEICOS’ approach to treat #mitochondrialdisease

[OMEICOS Therapeutics @omeicos]

Thank you @EBDgroup for giving therapeutic innovations in #cardiology plenty of room at #BioEurope yesterday. Our CEO Robert Fischer joined representatives from @dzhk_germany, @evotec, @bayerpharma, Acesion & Dinaqor to discuss opportunities for all stakeholders in the field.

[OMEICOS Therapeutics @omeicos]

We’re delighted to announce that Dr Simon Russell has joined OMEICOS as CBO. Simon brings with him over 30 years of biopharma R&D, commercial and business development experience, making him a valuable addition to our management team. Welcome, Simon! https://t.co/GnLvYBiJY6

[OMEICOS Therapeutics @omeicos]

With the first #AFib patients being dosed in our Phase 2 PROMISE-AF clinical study, a new chapter has begun for OMEICOS. We took the opportunity to update our company website and present our story in a fresh look & feel: https://t.co/dJGYA71cwn

[OMEICOS Therapeutics @omeicos]

We have dosed first patients with Atrial Fibrillation in our Phase 2 study for OMT-28: https://t.co/S5BcLUj9fk The trial should deliver clinical proof of concept in H1/2020 & determine the Phase 3 dosing regimen for our novel approach to stabilize the heart rhythm #AFib

[OMEICOS Therapeutics @omeicos]

Thanks to @JNJNews for sending the participants of its annual senior leadership development program to the @MDC_Berlin campus this week. Had a great exchange on how our science may disrupt the #Afib & #ophthalmology markets and our learning curve as a fast-growing organization.

[OMEICOS Therapeutics @omeicos]

We’re thrilled to announce the appointment of Christian Schetter to our Board. Christian has over 20 years' industry experience across the life sciences sector and was instrumental in building German immuno-oncology company #Rigontec. Welcome Christian! https://t.co/tyzsupNBZl

[OMEICOS Therapeutics @omeicos]

Nominated for the Innovationspreis Berlin-Brandenburg @InnoPreis. Out of 174 initial applications, @Omeicos reached the final shortlist of 10 companies. The awards ceremony will take place on November 30. Keep your fingers crossed! #OurHeartsBeatforBerlin https://t.co/hLwytdUYkA

[OMEICOS Therapeutics @omeicos]

Wir freuen uns über die Nominierung zum Innovationspreis Berlin-Brandenburg @InnoPreis. Gegen 174 Einreichungen behauptet und in die Finalrunde eingezogen. Preisverleihung ist am 30. November. Drückt uns die Daumen! #OurHeartsBeatforBerlin https://t.co/hLwytdUYkA

[OMEICOS Therapeutics @omeicos]

@SBungers @gruenderszene Thanks, Simon

[OMEICOS Therapeutics @omeicos]

OMEICOS will present at @EBDgroup’s #BIOEurope in Copenhagen – Join our company presentation on Tuesday, November 6th (Cardiovascular Track) or reach out via the partnering system to learn about our approach in #AFib and #wetAMD: https://t.co/OAWeGcyqFT #BEU18